Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 192 participants.

Also called NCT06682000

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 192 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06682000
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06682000. Randomized; double masking; primary purpose treatment. Start 2025-01-20 (actual); primary completion 2025-10-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension
Condition
Hypertension
Condition
Essential Hypertension
Intervention (Drug)
DWC202404, DWC202314
Intervention (Drug)
DWC202404, DWC202314P
Lead sponsor
Daewoong Pharmaceutical Co. LTD. (class: industry)

Record details

Record id
cardio:ct-nct06682000
Content hash
5fb9d307974cb1408deecf2f2e6e8f9b0bf703717338b783d54f036a98f3b42d